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Abstract
Allergen immunotherapy (AIT) is widely used in clinical practice for patients with moderate to severe allergic rhinitis due
to inhalant allergens and may be delivered via subcutaneous (SCIT) and sublingual routes (SLIT). However, the quality of
evidence for individual AIT products is very heterogeneous, and extensions of overall conclusions (“class effects”) on the
efficacy and disease-modifying effects to all AIT products are unjustified. In contrast, each product needs to be evaluated
individually, based on available study results, to justify efficacy and specific claims on sustained and disease modifying
effects per allergen and targeted patient group (children vs. adults, allergic rhinitis vs. asthma). WAO intends to support
the current development to evidence-based AIT, which ultimately will lead to a more efficacious treatment of allergic
patients and the appropriate recognition of AIT.
Allergen immunotherapy (AIT) is a recommended thera-
peutic option for patients with moderate to severe allergic
rhinitis with, or without, mild to moderate asthma due to
inhalant allergens [1–4]. AIT is considered a disease-
modifying treatment based on the long-term symptom re-
lief, even after cessation of treatment. Furthermore, AIT
has a documented ability to prevent both the onset of new
allergic sensitizations and the development of comorbidities
of allergic rhinitis like allergic asthma [5].
There are currently two routes of administration of AIT:
subcutaneous (SCIT) and sublingual immunotherapy
(SLIT). Several clinical trials and metaanalyses provide evi-
dence to support the efficacy and safety of AIT and its
widespread use in clinical practice [6]. However, the many
trials are very heterogeneous in nature, especially in terms
of the type and quality of allergen product used, treatment
schedules and the target populations. Consequently, there
is a considerable degree of heterogeneity of results in the
metaanalyses [7]. This prevents extension of the overall
conclusions (class effect) made with respect of each of the
individual products contributing to the metaanalysis. More
reliable evidence derived from large clinical trials with a
specific product and a commonly used dose schedule is
crucial. It is therefore a matter of considerable concern that
the efficacy of certain products in clinical trials e.g. demon-
strating long-term or disease modifying effects is often
claimed as a blanket approval for all products administered
via the same application route. In fact, some products have
even been marketed without ever being tested by appropri-
ate studies (dependent on the local regulations and the year
of introduction), as those studies were not asked for, or ever
registered (“named patient products”). Furthermore, some
of the products that have been marketed for decades have
failed to demonstrate clinical efficacy when tested using
standard clinical trials [8].
It is likely that there has been an underreporting of
negative results in the past, since only a few clearly
negative studies have been published. This highlights the
fact that: 1) not all AIT products are effective, or equally
effective, and 2) the efficacy claims based on a “class ef-
fect”, without supporting evidence for an individual
product (involving the design and conduct of rigorous
clinical trials), are inappropriate. In fact, it should be
understood that the optimistic assumptions for AIT (“class
effect”) mentioned above, may be unjustified in a general
sense, as the evidence (specifically for long-term efficacy,
prevention of asthma and efficacy in children) relies on the
results generated with a limited number of products that
have undergone well-designed studies. It has been clearly
demonstrated in the past that such assumptions may be in-
correct with respect to some products that are not well
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studied [8]. So far, despite the absence of persuasive data
from well designed and performed studies, potentially inef-
fective products continue to be widely used by the medical
community.
In the last decade, substantial progress has been made
in the development of selected AIT products and based
on the current state-of-the-art, there are high quality,
adequately powered, double-blind, placebo-controlled,
randomized (DBPCR) clinical trials in which a small
number of products have been evaluated. From these
studies, it is possible to estimate the therapeutic efficacy
of specific products as well as their safety profile. On the
basis of these studies, recommendations for the use of indi-
vidual products can be made in specific patient groups.
This systematic and rigorous evaluation is mandatory and
vital, not only for newly developed products, but also for
those already in the market for a long time. For many prod-
ucts, specifically for mixtures of allergens, conclusive and
reliable studies have never been performed and claims for
their efficacy are unjustified. Furthermore, evaluation needs
to be performed not only on a product line basis, but also
per allergen, as single products of a product line contain
different allergens [8]. Finally, safety and efficacy in children
and adults should be evaluated through separate studies.
As an example, an evidence-based evaluation ap-
proach was officially adopted in Europe by the German
authorities (Federal Ministry of Health and Paul-
Ehrlich-Institute, PEI) in 2008, to be followed for all
products in the market as named patient products and
for products to be newly registered for the treatment
of allergies due to the most frequent allergens: grass
pollen, tree pollens (birch, hazel, elder), house dust
mite (Dermatophagoides pteronyssinus and farinae),
bee and wasp venom (Therapy Allergen Ordinance,
Therapie-Allergene Verordnung; TAV 2008). These
rules also apply to mixtures involving at least one of
the mentioned common allergens. This approach led
to the elimination of more than 6,000 products for
which efficacy had never been demonstrated. Import-
antly, these rules do not apply for less frequent aller-
gens (such as rare inhalant or occupational allergens)
since the authorities recognize that the financial bur-
den would be too great or study participants are im-
possible to be found for products with small market
indications. Apart from efficacy and safety, the quality
of allergen extracts is subjected to control by the au-
thority, including testing every new batch of allergen
extract (batch release) for consistency.
Such regulatory prescriptions are intended to ensure
the safety and efficacy of frequently used allergen
products (at the dose actually recommended by the
manufacturer) and aim to exclude ineffective, unsafe,
or low quality products from market access. In the
medium- to long-term period, these measures will
support and encourage the use of AIT, since clear evi-
dence of efficacy and safety is the mandatory basis for
the application of AIT in the treatment of allergic pa-
tients and for reimbursement. In many countries such
regulations do not exist [9], or the approach to AIT
differs [10] and, thus, hundreds of AIT products, for
which high quality evidence of safety and efficacy have
not been collected, continue to be available. Moreover,
the terms “SCIT” and “SLIT” are frequently used as
“umbrella” descriptions in order to exploit the positive
connotations associated with AIT based on positive
clinical trials of a limited number of products. Such
marketing strategies wrongly imply that products are
effective in reducing symptoms and modifying disease,
for example, reducing the risk of developing asthma,
when there is no objective supportive evidence. This
situation is detrimental, as it does not allow physicians
and health professionals to base their selection of
treatment on individual products which have demon-
strated safety and efficacy. At this time, the selection of
safe and efficacious products is possible for both SCIT
and SLIT, since selected products have been shown to
achieve objective evidence of efficacy and safety. It is,
therefore, obvious that such products should be pre-
ferred whenever possible.
WAO intends to support and encourage this important
evidence-based development in the field of AIT for fre-
quently encountered allergens, by providing this document
that details the expectations that a product should fulfill, in
order to be recommended for safe and effective use. In con-
trast, differentiation and/or marketing of products merely
based on application routes and claims of safety and effi-
cacy for a particular product that has not been substanti-
ated with objective evidence should be discouraged.
The minimum requirements for a product that can be
recommended for use, should include publication in the
peer-reviewed literature of at least one successful state-of-
the-art DBPCR trial in adults for the first year of treatment
[11–13], possibly preceded by a dose response/dose finding
study (for which provocation testing may be used) to deter-
mine the optimal dosage. Such studies should be performed
with standardized extracts, with clearly defined doses, being
included in clinical trials registers (e.g. clinicaltrials.gov,
clinicaltrialsregister.eu), having an adequate sample size/
statistical power to detect a meaningful clinical effect
(combined symptom and medication scores), following
recommendations on appropriate outcome measures,
study conduct and reporting as defined in the recent
literature [14, 15]. When possible, adherence/compli-
ance should be measured and reported. Allergen prod-
ucts have the capacity to modify the immune system and
are considered medicinal products with the need of a mar-
keting authorization. The European Medicines Agency
(EMA) is responsible for EU-wide registration of allergen
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products [16, 17]. The quality, safety and clinical efficacy
of allergen products for the authorization processes
have to be documented through a straightforward de-
velopment plan as outlined in the EMA-guidance on
the “Clinical Development of Products for Specific Im-
munotherapy for The Treatment of Allergic Diseases”
[18]. Different procedures are followed in other coun-
tries such as the US [10]. A robust recommendation for
the use of a specific product can be based on a marketing
authorization fulfilling the requirements of the Directive
2001 within the EU [19], based on the state-of-the-art proof
of the quality, safety and efficacy of the product. These
products answer to the requirements in respect of EMA
guidelines and undergo a regular pharmacovigilance.
Claims on sustained effects of a product should be based
on at least one DBPCR study, with appropriate sample size
calculation, over 3 years of treatment. Demonstration of a
disease modifying effect is based on studies with a blinded
follow-up for at least two consecutive years after AIT dis-
continuation, while monitoring of symptoms is maintained.
Claims for efficacy and safety in children should be based
on appropriate DBPCR studies in the pediatric age group.
Furthermore, for specific claims, e.g. in asthmatics, appro-
priate DBPCR studies should be performed in an appropri-
ate patient group, with objective measurements.
In this document, we have refrained from mentioning in-
dividual products. Rather, we have attempted to elaborate
upon the criteria for evidence-based recommendation of
products. This information/evidence can then be used by:
[1] physicians as a useful guide to which products to ad-
minister to patients for a safe and efficacious outcome and
[2] health authorities with regard to reimbursement based
on proven cost-effectiveness. As the availability of such
products may vary from country to country, an individual-
ized approach may be needed. However, the aim of identify-
ing safe and efficacious products that can be recommended
for treatment and reimbursement in individual countries,
through an evidence-based evaluation of each individual
product, should not be compromised (Tables 1 and 2).
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